5 years later - overview of the data collected in ACROSTUDY - different treatment regimens, database structure, basic strategies and safety.

2.50
Hdl Handle:
http://hdl.handle.net/10541/81974
Title:
5 years later - overview of the data collected in ACROSTUDY - different treatment regimens, database structure, basic strategies and safety.
Authors:
Trainer, Peter J
Abstract:
ACROSTUDY is an observational registry intended to collect safety and efficacy data on pegvisomant therapy. 792 patients have been enrolled, of whom 83% had commenced pegvisomant prior to recruitment. The mean follow-up is 1.66 years with the mean duration of pegvisomant therapy 3.31 years representing 2625 patient years of treatment. 90% of patients were on once daily pegvisomant, and 67% were on monotherapy. Disappointingly IGF-I was normalised in less than 70% of patients, furthermore in 80% of patients with an elevated IGF-I the daily dose of pegvisomant was 20 mg or less. 56 Serious Adverse Events (SAEs) were reported, 13 of which were related to pegvisomant. 276 Adverse Events (AEs) were reported, of which 56 were considered related to pegvisomant. The AEs most frequently attributed to pegvisomant were disturbed liver function tests and injection site reactions. MRI imaging was available in 684 patients. 411 patients had at least one MRI on pegvisomant compared to a baseline. In 31 patients a decrease in tumour size has been reported, of whom 20 had previously received radiotherapy. An increase in tumour size has been reported and confirmed in 22 patients. In 11 patients there was contradictory data on tumour size, while in 6 patients central review of the films failed to confirm increase in tumour size. In conclusion the safety data are generally reassuring while the IGF-I normalisation rate is disappointing which probably reflects a failure of dose titration. Further effort is needed to understand the reasons for the failure of dose titration.
Affiliation:
P Trainer, Department of Endocrinology, Christie Hospital, Manchester, United Kingdom.
Citation:
ACROSTUDY -5 years later - overview of the data collected in ACROSTUDY - different treatment regimens, database structure, basic strategies and safety. 2009: Eur. J. Endocrinol.
Journal:
European Journal of Endocrinology
Issue Date:
14-Aug-2009
URI:
http://hdl.handle.net/10541/81974
PubMed ID:
19684052
Type:
Article
Language:
en
ISSN:
1479-683X
Appears in Collections:
All Christie Publications ; Endocrinology

Full metadata record

DC FieldValue Language
dc.contributor.authorTrainer, Peter J-
dc.date.accessioned2009-09-22T09:21:25Z-
dc.date.available2009-09-22T09:21:25Z-
dc.date.issued2009-08-14-
dc.identifier.citationACROSTUDY -5 years later - overview of the data collected in ACROSTUDY - different treatment regimens, database structure, basic strategies and safety. 2009: Eur. J. Endocrinol.en
dc.identifier.issn1479-683X-
dc.identifier.pmid19684052-
dc.identifier.urihttp://hdl.handle.net/10541/81974-
dc.description.abstractACROSTUDY is an observational registry intended to collect safety and efficacy data on pegvisomant therapy. 792 patients have been enrolled, of whom 83% had commenced pegvisomant prior to recruitment. The mean follow-up is 1.66 years with the mean duration of pegvisomant therapy 3.31 years representing 2625 patient years of treatment. 90% of patients were on once daily pegvisomant, and 67% were on monotherapy. Disappointingly IGF-I was normalised in less than 70% of patients, furthermore in 80% of patients with an elevated IGF-I the daily dose of pegvisomant was 20 mg or less. 56 Serious Adverse Events (SAEs) were reported, 13 of which were related to pegvisomant. 276 Adverse Events (AEs) were reported, of which 56 were considered related to pegvisomant. The AEs most frequently attributed to pegvisomant were disturbed liver function tests and injection site reactions. MRI imaging was available in 684 patients. 411 patients had at least one MRI on pegvisomant compared to a baseline. In 31 patients a decrease in tumour size has been reported, of whom 20 had previously received radiotherapy. An increase in tumour size has been reported and confirmed in 22 patients. In 11 patients there was contradictory data on tumour size, while in 6 patients central review of the films failed to confirm increase in tumour size. In conclusion the safety data are generally reassuring while the IGF-I normalisation rate is disappointing which probably reflects a failure of dose titration. Further effort is needed to understand the reasons for the failure of dose titration.en
dc.languageENG-
dc.language.isoenen
dc.subjectPegvisomant Therapyen
dc.subjectTreatment Optionsen
dc.subjectTumouren
dc.subjectCanceren
dc.subjectSomatostatinen
dc.title5 years later - overview of the data collected in ACROSTUDY - different treatment regimens, database structure, basic strategies and safety.en
dc.typeArticleen
dc.contributor.departmentP Trainer, Department of Endocrinology, Christie Hospital, Manchester, United Kingdom.en
dc.identifier.journalEuropean Journal of Endocrinologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.